Xenon Pharmaceuticals shares fall 22.6% premarket on pause in enrollment for depression studies

Xenon Pharmaceuticals shares fell about 22.6% in premarket trading after the company paused enrollment in its depression studies, according to a report citing the enrollment halt.

Detected & updated continuously · Source: Nebula